2020
Stem Cell Therapy for Thromboangiitis Obliterans (Buerger’s Disease)
Dash B, Peyvandi H, Duan K, Richardson E, Ndon S, Gabrick K, Faz A, Persing J, Dardik A, Hsia H. Stem Cell Therapy for Thromboangiitis Obliterans (Buerger’s Disease). Processes 2020, 8: 1408. DOI: 10.3390/pr8111408.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsThromboangiitis obliteransYoung male smokersBuerger's diseaseImmunomodulatory approachesMale smokersSurgical bypassPathological findingsTreatment modalitiesVascular diseaseDefinitive cureLower extremitiesMedium arteriesLesion treatmentTherapeutic modalitiesTAO treatmentTherapeutic angiogenesisCell therapyDiseaseObliteransStem cellsCurrent knowledgeModalitiesTreatmentPotential optionVasculitis
2006
Presence of prostacyclin receptor in arteriosclerotic human femoral artery.
Muto A, Kondo Y, Yamamoto Y, Yamada H, Washimi O, Miyauchi Y, Kudo F, Dardik A, Nishibe T. Presence of prostacyclin receptor in arteriosclerotic human femoral artery. International Angiology 2006, 25: 175-8. PMID: 16763535.Peer-Reviewed Case Reports and Technical NotesConceptsFemoral arteryVascular endothelial cellsEndothelial cellsArteriosclerosis obliteransHuman femoral arteriesProstacyclin analogueIP receptorProstacyclin receptorLuminal sideVon Willebrand factorIschemic symptomsVascular eventsRelaxant effectLower extremitiesCardiovascular homeostasisLimb amputationAtherosclerotic lesionsPositive cellsArterySingle immunohistochemistryWillebrand factorReceptorsStrong expressionObliteransPatients